Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Hold" at Wall Street Zen

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Sunday.

A number of other equities analysts have also recently weighed in on PTGX. Wedbush reissued an "outperform" rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a report on Friday, March 28th. Truist Financial boosted their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a report on Tuesday, March 11th. The Goldman Sachs Group dropped their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, February 24th. BTIG Research set a $73.00 target price on Protagonist Therapeutics in a research note on Monday, March 3rd. Finally, BMO Capital Markets upped their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $65.44.

Protagonist Therapeutics Stock Up 1.0%

NASDAQ PTGX opened at $54.38 on Friday. Protagonist Therapeutics has a fifty-two week low of $30.67 and a fifty-two week high of $60.60. The stock has a market cap of $3.37 billion, a price-to-earnings ratio of 20.44 and a beta of 2.25. The business has a fifty day moving average of $45.60 and a 200-day moving average of $43.02.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $28.32 million during the quarter, compared to analysts' expectations of $30.44 million. As a group, analysts anticipate that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the sale, the director now owns 13,130 shares of the company's stock, valued at approximately $712,302.50. The trade was a 23.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Asif Ali sold 1,756 shares of the business's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total value of $80,776.00. Following the sale, the chief financial officer now directly owns 61,065 shares of the company's stock, valued at approximately $2,808,990. This trade represents a 2.80% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 61,173 shares of company stock valued at $3,461,180. Company insiders own 4.90% of the company's stock.

Institutional Investors Weigh In On Protagonist Therapeutics

A number of institutional investors have recently added to or reduced their stakes in PTGX. KBC Group NV grew its position in Protagonist Therapeutics by 54.4% during the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock valued at $81,000 after acquiring an additional 737 shares during the period. Louisiana State Employees Retirement System boosted its position in shares of Protagonist Therapeutics by 1.1% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock worth $1,112,000 after buying an additional 300 shares during the period. Principal Financial Group Inc. boosted its position in shares of Protagonist Therapeutics by 5.3% in the fourth quarter. Principal Financial Group Inc. now owns 337,809 shares of the company's stock worth $13,039,000 after buying an additional 16,977 shares during the period. Handelsbanken Fonder AB purchased a new stake in shares of Protagonist Therapeutics in the fourth quarter worth about $679,000. Finally, Hussman Strategic Advisors Inc. purchased a new stake in shares of Protagonist Therapeutics in the fourth quarter worth about $4,053,000. Hedge funds and other institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.